GSK announces positive results for treatment of anaemia in CDK patients
By Alexander Bueso
Date: Friday 16 Jul 2021
(Sharecast News) - GlaxoSmithKline announced positive headline results from studies into its treatment of patients suffering from anaemia due to chronic kidney disease, Daprodustat.
In particular, GSK's chief scientific officer, Hal Barron, highlighted the results from the ASCEND-ND and ASCEND-D studies given the need to manage cardiovascular outcomes for such patients and the convenience of oral treatments.
"We will continue to analyse the data from the robust phase 3 ASCEND programme and look forward to working closely with regulators as we plan for our submissions," Barron added.
Each of the five studies in GSK's third phase ASCEND programme met their respective primary or co-primary endpoints.
The company also noted that Daprodustat was "generally" well-tolerated in both non-dialysis and dialysis patients.
Thus far Daprodustat had only been approved by for use by Japanese authorities in patients with renal anaemia.
ASCEND had enrolled more than 8,000 patients who were treated for up to 3.75 years.
As of 1349 BST, shares of GSK were trading higher by 0.60% at 1,415.4p.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN